Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomized controlled trial, published in The Lancet journal. However, the patients treated at home with molnupiravir recovered quicker compared to the control group.
from Medical Xpress - latest medical and health news stories https://ift.tt/oq96Fsb
